Navigation Links
DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/10/2012

GAITHERSBURG, Md., Jan. 10, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today a collaborative agreement between DFH and the National Cancer Institute (NCI) to further the development of the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus.

The collaboration will involve extending successful efforts by DFH Pharma to identify drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. DFH scientists have identified a series of 2nd generation maturation inhibitors with the broad anti-viral activity profile necessary for successful HIV drug development. The NCI investigators will evaluate the activity of these compounds against HIV strains associated with reduced bevirimat activity. The most potent of these compounds will be selected for further pre-clinical testing with a goal of initiating human clinical trials with one or more candidate molecules in the near future.

Dr. Eric Freed, an internationally recognized leader in the field of HIV assembly and release, will head the NCI group. Dr. Freed has worked in the maturation inhibition area since the early 2000's when his group collaborated with Panacos Pharmaceuticals in the discovery and characterization of the maturation inhibitor class of HIV drugs. "We are very excited to be working with Dr. Freed and his NCI colleagues in developing this new class of drugs to treat HIV infection"' said Carl Wild, Ph.D., President and CEO. Dr. Wild continued, "The NCI collaboration will allow DFH to build on its recent success in identifying broadly active maturation inhibitor drug candidates and expedite the return of this exciting class of HIV drug to the clinic."

About Maturation Inhibitors

Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with virus maturation. Specifically, drugs in this class interfere with the last step in the processing of the HIV-1 Gag protein. This interference leads to the formation of noninfectious, immature virus particles, thus preventing subsequent rounds of HIV infection. As expected for a novel mechanism of action, these drugs retain inhibitory activity against HIV-1 isolates resistant to all classes of currently approved drugs commonly used by HIV infected patients. DFH plans to develop maturation inhibitors for application in both first-line and salvage therapy.

The clinical proof-of-concept for maturation inhibitors was established in a monotherapy study in HIV-infected patients with the first-in-class inhibitor bevirimat. While this first generation drug candidate was shown to be safe and well-tolerated with potent antiviral activity in some patients, only limited activity was observed in other patients. The focus of the second generation program is to identify drug candidates with potent activity against all HIV-1 strains, including those that exhibit reduced sensitivity to first-generation compounds.

About DFH Pharma, Inc.

DFH Pharma was founded by Dr. Wild and David E Martin, PharmD in 2011. Dr. Wild was a co-founder of Panacos Pharmaceuticals and served as the Chief Scientific Officer. He serves as the company's President and Chief Executive Officer as well as on the Board of Directors. While at Duke University, Dr. Wild discovered the Fusion Inhibitor class of HIV drugs and invented the first approved member of that drug class, Fuzeon® (Enfuvirtide). Dr. Martin was Senior Vice President, Drug Development and Regulatory Affairs at Panacos. He serves as the Chief Development Officer and on the Board of Directors. While at Panacos, Drs. Wild and Martin played critical roles in the development of bevirimat, the first-in-class maturation inhibitor drug. Together the DFH Pharma team has more than 60 years of experience in antiviral drug discovery and development.

Contact:
Carl Wild, PhD
cwild@dfhpharma.com
Telephone: (301) 461-4231

or

David E. Martin, PharmD
dmartin@dfhpharma.com
Telephone: (301) 538-1878

Media Contact: David Martin DFH Pharma, Inc., 301-538-1878, dmartin@dfhpharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
4. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
5. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
6. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... , April 27, 2017  Kinexum, a distinguished resource ... today announces the appointment of Thomas C. Seoh ... ("Zan") Fleming, M.D., Kinexum founder, who becomes Executive Chairman ... to Kinexum clients. Thomas Seoh ... the Kinexum mission and lead the firm,s remarkable team ...
(Date:4/26/2017)... Beach, SC (PRWEB) , ... April 26, 2017 ... ... the mind, has teamed up with NASA to showcase the future of deep ... Space Launch System (SLS) rocket and Orion spacecraft and includes a guest appearance ...
(Date:4/26/2017)... CO (PRWEB) , ... April 25, 2017 , ... LABS, ... offerings were added to its extensive test menu: Nucleic Acid Testing (NAT) for ... time, LABS was only able to offer NAT screening for blood donors under an ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... EMEA and North America this May on the following dates: ... Donald H. Taylor, Chairman of the Learning and Performance Institute will be the ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):